Patient Reported Outcomes Burdens and Experiences - Phase 3

Chronic Disease Clinical Trial

— PROBE-3  

Official title:

Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03549858
• Other study ID #: PROBE-3
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: December 31, 2026

Study information

• Verified date: January 2024
• Source: McMaster University
• Contact: Mark Skinner
• Phone: 202.253.8342
• Email: mskinnerdc[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.

Description:

BACKGROUND The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development. CURRENT STUDY and FUTURE DIRECTIONS Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data). The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used. At the same time, the research framework will have the potential for: - Expanding country participation within existing and new regions. - Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries. - Using PROBE in new countries - Testing the performance of the PROBE questionnaire in new patient populations INVESTIGATION TEAM Principal Investigator: 1. Mark Skinner JD, Institute for Policy Advancement Ltd. (US) Co-Investigators: 2. Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada) 3. Randall Curtis MBA, Factor VIII Computing (US) 4. Neil Frick MS, National Hemophilia Foundation (US) 5. Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US) 6. Declan Noone, Irish Hemophilia Society (Ireland) 7. David Page, Canadian Hemophilia Society (Canada) 8. Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US) 9. Brian O'Mahoney, Irish Hemophilia Society (Ireland) 10. Chatree Chai-Adisaksopha, MD MSc.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• PWH will be recruited through national hemophilia patient organizations utilizing their existing membership rosters, social media outlets and meetings / events. The investigators are not proposing a pre-determined method of PWH recruitment. They will utilize the information acquired in the workshop and take-home project to inform best practice in recruitment methodology for the study. The investigators may consider requesting different countries test different PWH recruitment strategies to test reproducibility. In the future, the questionnaire might also be administered to patients with other chronic conditions.

Exclusion Criteria:

• Disease severity and Age bands or age limits (e.g. = Age 18) may be utilized to narrow the study population.

Related Conditions & MeSH terms

• Chronic Disease
• Hemophilia

Intervention

Other:
• Quality of life measure (survey)
The QoL tool is a questionnaire

Locations

Country	Name	City	State
Canada	McMaster University	Hamilton	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
McMaster University	National Hemophilia Foundation, Patient Outcomes Research Group (PORG)

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Skinner MW, Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker JS, Iorio A. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot Feasibility Stud. 2018 Feb 27;4:58. doi: 10.1186/s40814-018-0253-0. eCollection 2018. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Between-countries variability of the PROBE score	Mean difference and standard deviation of the PROBE score between countries.	2 years
Secondary	Within-countries variability of the PROBE score	Mean difference and standard deviation of the PROBE score in repeated assessments within countries.	2 years
Secondary	Within-countries comparison of the PROBE score in PWH against national normative data	Mean difference and standard deviation of the PROBE score in PWH against national normative data within countries.	2 years